# L3Harris Technologies financial and strategic developments

> Live situation record from CLSTR: https://clstr.news/situations/l3harris-technologies-financial-and-strategic-developments
> Updated: 2026-08-08T06:14:27.000Z. Sources: 2. Developments: 2.

L3Harris Technologies reported strong second-quarter 2026 financial results, including $5.9 billion in revenue and a record $42 billion order backlog. Despite these earnings and raised full-year guidance, the company's stock fell 11% following the announcement that it would postpone the initial public offering and spinoff of its missile business until next year due to market conditions. During this period, the Royal Bank of Canada reduced its stake in the company.

## Timeline

### 2026-08-08: Institutional investors increase stakes in L3Harris and Nurix Therapeutics

Institutional investors have increased stakes in L3Harris Technologies and Nurix Therapeutics, according to recent SEC filings and analyst reports.

2 sources. https://clstr.news/cluster/institutional-investors-increase-stakes-in-l3harris-and-nurix-therapeutics

### 2026-07-29: L3Harris Technologies Shares Drop 11% After Strong Q2 Results and Missile IPO Delay

L3Harris posted strong Q2 2026 results—$5.9B revenue, record $42B backlog—but shares fell 11% after delaying its missile unit IPO, and RBC trimmed its stake.

10 sources. https://clstr.news/cluster/l3harris-technologies-posts-8-revenue-rise-in-q2-2026

---
Cite as: L3Harris Technologies financial and strategic developments. CLSTR, https://clstr.news/situations/l3harris-technologies-financial-and-strategic-developments